- Zacks•19 hours ago
Bristol-Myers Squibb Company (BMY) announced that its supplemental biologics license application (sBLA) for immuno-oncology drug Opdivo has been accepted for priority review by the FDA.
- Zacks•20 hours ago
Given the growing importance of this segment of the cancer market, it makes sense to keep an eye on the performance of immuno-oncology (IO) treatments already on the market.
- Business Wire•22 hours ago
Bristol-Myers Squibb’s Coast 2 Coast 4 Cancer has raised more than $1,050,000 to support Stand Up To Cancer’s collaborative cancer research programs. In this third year of the relay, six teams of BMS employees -- with 80 employees in total -- set out on September 7 to bike 2,800 miles in 21 days from the Oregon Coast to the New Jersey shore to support Stand Up To Cancer, whose collaborative “Dream ...
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||49.03 x 100|
|Ask||49.35 x 100|
|Day's Range||49.04 - 50.17|
|52wk Range||49.04 - 77.12|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.79|
|Avg Vol (3m)||14,221,986|
|Dividend & Yield||1.52 (3.04%)|